{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:38:53Z","timestamp":1792784333343,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"crossref","award":["F32NS070356"],"award-info":[{"award-number":["F32NS070356"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UNC Gene Therapy Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.neuropharm.2012.03.004","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T20:06:54Z","timestamp":1332014814000},"page":"82-88","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["Adeno-associated virus (AAV) gene therapy for neurological disease"],"prefix":"10.1016","volume":"69","author":[{"given":"Marc S.","family":"Weinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jude","family":"Samulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"McCown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.03.004_bib1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.nbd.2003.08.002","article-title":"Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats","volume":"14","author":"Arvidsson","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1227\/01.neu.0000279944.12903.2c","article-title":"Analyses of a Phase 1 Clinical Trial of Adeno-associated Virus-Nerve Growth Factor (CERE-110) Gene Therapy in Alzheimer\u2019s Disease","volume":"61","author":"Bakay","year":"2007","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/exnr.2000.7408","article-title":"Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in\u00a0vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach","volume":"164","author":"Bankiewicz","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib4","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.185","article-title":"Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington\u2019s disease","author":"Boudreau","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroscience.2005.11.057","article-title":"Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain","volume":"138","author":"Broekman","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/(SICI)1097-4547(19990215)55:4<504::AID-JNR10>3.0.CO;2-0","article-title":"Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus","volume":"55","author":"Chen","year":"1999","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/mt.2008.111","article-title":"Biodistribution of Adeno-associated Virus Type-2 in nonhuman primates after convection-enhanced delivery to brain","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib10","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/mt.2009.216","article-title":"Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates","volume":"18","author":"Dodiya","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.410320504","article-title":"Adenosine: a potential mediator of seizure arrest and postictal refractoriness","volume":"32","author":"During","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nm1197-1295","article-title":"New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors","volume":"3","author":"Ferrari","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","article-title":"A\u00a0dose-ranging study of AAV-hAADC Therapy in Parkinsonian monkeys","volume":"14","author":"Forsayeth","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.gt.3302961","article-title":"Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice","volume":"14","author":"Fu","year":"2007","journal-title":"Gene. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/exnr.2002.8006","article-title":"Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer","volume":"177","author":"Georgievska","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11920-010-0097-7","article-title":"The role of MeCP2 in brain development and neurodevelopmental disorders","volume":"12","author":"Gonzales","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2009.292","article-title":"Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB)","volume":"18","author":"Gray","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett Syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib23","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1128\/JVI.74.18.8732-8739.2000","article-title":"Novel transcriptional signals in the adeno-associated virus terminal repeat A\/D junction element","volume":"74","author":"Haberman","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/mthe.2002.0701","article-title":"Therapeutic liabilities of in\u00a0vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity","volume":"6","author":"Haberman","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nm901","article-title":"Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion","volume":"9","author":"Haberman","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/hum.2008.151","article-title":"Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response","volume":"20","author":"Hadaczek","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/hum.2006.17.291","article-title":"Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain","volume":"17","author":"Hadaczek","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/hum.2006.17.807","article-title":"Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors","volume":"17","author":"Harding","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib29","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Gene Therapy of Canavan Disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/hum.2008.137","article-title":"Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys","volume":"20","author":"Johnston","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1094-148","article-title":"Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain","volume":"8","author":"Kaplitt","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib35","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","article-title":"Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF","volume":"30","author":"Kells","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy-based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib37","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1523\/JNEUROSCI.20-12-04686.2000","article-title":"Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson\u2019s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system","volume":"20","author":"Kirik","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ymthe.2005.10.008","article-title":"Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins","volume":"13","author":"Klein","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.mt.6300331","article-title":"AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method","volume":"16","author":"Klein","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/exnr.1997.6736","article-title":"Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors","volume":"150","author":"Klein","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3171\/jns.2005.103.5.0923","article-title":"Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents","volume":"103","author":"Krauze","year":"2005","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib43","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.2440-10.2010","article-title":"An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson\u2019s disease","author":"Laganiere","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib44","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/mt.2009.170","article-title":"Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates","volume":"17","author":"Lawlor","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib45","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/mt.2009.196","article-title":"Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2009.286","article-title":"Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain","volume":"18","author":"Markakis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib47","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/gt.2011.10","article-title":"Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design","volume":"18","author":"Martin","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/WNR.0b013e328338ba00","article-title":"Efficient gene transfer into neurons in monkey brain by adeno-associated virus 8","volume":"21","author":"Masamizu","year":"2010","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib50","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(95)01488-8","article-title":"Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector","volume":"713","author":"McCown","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib52","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nn.2535","article-title":"Selective induction of astrocytic gliosis generates deficits in neuronal inhibition","volume":"13","author":"Ortinski","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1126\/science.1116916","article-title":"Astrocytic purinergic signaling coordinates synaptic networks","volume":"310","author":"Pascual","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib54","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1128\/JVI.77.12.7034-7040.2003","volume":"77","author":"Passini","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib55","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1128\/JVI.78.13.6808-6817.2004","article-title":"Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats","volume":"78","author":"Paterna","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0270(00)00183-7","article-title":"Adeno-associated virus vectors: activity and applications in the CNS","volume":"98","author":"Peel","year":"2000","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/WNR.0b013e328348bff5","article-title":"Comparison of AAV2 and AAV5 in gene transfer in the injured spinal cord of mice","volume":"22","author":"Peng","year":"2011","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib58","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A\u00a0tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.21715","article-title":"Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome","volume":"66","author":"Ramocki","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib61","doi-asserted-by":"crossref","first-page":"11342","DOI":"10.1523\/JNEUROSCI.3329-06.2006","article-title":"Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy","volume":"26","author":"Raol","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib62","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1523\/JNEUROSCI.4056-03.2004","article-title":"Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus","volume":"24","author":"Richichi","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.neo.7900157","article-title":"A\u00a0hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy","volume":"3","author":"Ruan","year":"2001","journal-title":"Neoplasia"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib64","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1073\/pnas.79.6.2077","article-title":"Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells","volume":"79","author":"Samulski","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nm0797-771","article-title":"Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of \u03b2-glucuronidase","volume":"3","author":"Taylor","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/hum.2006.178","article-title":"Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain","volume":"18","author":"Taymans","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1528-1167.2010.02947.x","article-title":"Adenosine kinase as a target for therapeutic antisense strategies in epilepsy","volume":"52","author":"Theofilas","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/gt.2009.119","article-title":"Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6","volume":"17","author":"Towne","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0079-6123(09)17511-8","article-title":"Controlled dissemination of AAV vectors in the primate brain","volume":"175","author":"Varenika","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib70","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.gt.3302011","article-title":"Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain","volume":"10","author":"Wang","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/hum.2005.16.49","article-title":"Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors","volume":"16","author":"Watson","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib72","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/gt.2011.49","article-title":"The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5","volume":"18","author":"Weinberg","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib73","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2010.279","article-title":"MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression","volume":"19","author":"Xie","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib74","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.76.15.7651-7660.2002","article-title":"Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size","volume":"76","author":"Yang","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.neuropharm.2012.03.004_bib75","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/01.STR.31.3.745","article-title":"Estradiol exerts neuroprotective effects when administered after ischemic insult","volume":"31","author":"Yang","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2012.03.004_bib76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002100000309","article-title":"Extracellular metabolism of ATP and other nucleotides","volume":"362","author":"Zimmermann","year":"2000","journal-title":"Naunyn. Schmiedeberg. Arch. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:43:01Z","timestamp":1561470181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":75,"alternative-id":["S0028390812000883"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.03.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}